港股异动 | 云顶新耀(01952)午后涨超4% 公司与海森生物订立商业化服务协议及授权许可协议

Core Viewpoint - Genting New Year (01952) has seen a stock price increase of over 4%, currently trading at 45.8 HKD, with a transaction volume of 172 million HKD, following the announcement of two strategic cooperation agreements with Haisen Biopharmaceutical [1] Group 1: Strategic Agreements - Genting New Year’s wholly-owned subsidiary, Genting New Year Pharmaceutical Technology, has signed two strategic cooperation agreements with Haisen Biopharmaceutical [1] - Under the commercialization service agreement, Genting New Year Pharmaceutical Technology will leverage its existing sales and marketing system to provide commercialization services for six mature products from Haisen Biopharmaceutical, focusing on critical care, cardiovascular, and metabolic fields [1] Group 2: Licensing Agreement - The licensing agreement grants Genting New Year Pharmaceutical Technology exclusive rights to conduct further clinical development, registration, and commercialization of Lerodalcibep in Greater China, enhancing its late-stage pipeline [1] - According to the licensing agreement, Genting New Year Pharmaceutical Technology will make an initial payment of approximately 205 million CNY, with potential development and regulatory milestone payments not exceeding 212 million CNY, and potential sales milestone payments not exceeding 1.977 billion CNY, along with potential royalties based on net sales [1]